PMC studies how personalized medicine is reshaping the health care landscape with attention to the emergence of new tests and treatments as well as the policies and practices that influence whether personalized health care strategies are utilized in clinical settings.
![]() Personalized Medicine at FDA: The Scope & Significance of Progress in 2022 |
![]() Personalized Medicine at FDA: The Scope & Significance of Progress in 2020 |
![]() Personalized Medicine at FDA: A Progress & Outlook Report | ![]() The Evolution of Biomarker Use in Clinical Trials for Cancer Treatments: Key Findings and Implications |
![]() Personalized Medicine at FDA: 2017 Progress Report |
![]() Personalized Medicine at FDA: 2016 Progress Report | ![]() The Personalized Medicine Report: Opportunity, Challenges, and the Future (Fifth Edition) |
![]() Biopharmaceutical Companies’ Personalized Medicine Research Yields Innovative Treatments for Patients |
Daryl Pritchard, Ph.D., Senior Vice President, Science Policy
Lindsay Stephens, Senior Operations Manager and Secretary to the Board